N-Methylated Pomalidomide is primarily utilized in the field of medicinal chemistry and drug development, particularly in the treatment of certain types of cancers. It is an analog of pomalidomide, which is known for its immunomodulatory and anti-cancer properties. This compound is often investigated for its potential to enhance therapeutic efficacy or reduce side effects compared to its parent molecule. Researchers explore its application in targeting multiple myeloma and other hematologic malignancies, where it may inhibit tumor growth by modulating the immune system and inducing apoptosis in cancer cells. Additionally, it is studied for its role in cereblon-mediated protein degradation, a mechanism that can selectively degrade disease-causing proteins. Its methylated structure may also improve pharmacokinetic properties, such as bioavailability or metabolic stability, making it a promising candidate for further clinical development.